India, June 24 -- Wednesday, Quest Diagnostics Inc. (DGX) announced that the New York State Department of Health's Clinical Laboratory Evaluation Program has approved the company's Haystack MRD test for identifying residual or recurring disease in patients with a range of solid tumor cancers.
Upon receiving this approval, Haystack MRD, a circulating tumor DNA liquid biopsy test, is now authorized for patient testing in all 50 U.S. states.
The company stated that the approval is a proof point for Haystack MRD's quality and technical sophistication, which aims to deliver accurate testing to improve patient care.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
"Haystack MRD was designed to give oncologi...